Nangaku, Masaomi http://orcid.org/0000-0001-7401-2934
Ueta, Kiichiro http://orcid.org/0000-0002-3489-6971
Nishimura, Kenichi
Sasaki, Kazuyo http://orcid.org/0000-0001-5267-8284
Hashimoto, Takafumi
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
Article History
Received: 29 March 2023
Accepted: 31 October 2023
First Online: 26 March 2024
Declarations
:
: M. Nangaku received honoraria, advisory fees, or research funding from Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd, Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., GlaxoSmithKline K.K., Japan Tobacco Inc., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corporation. K. Ueta, K. Nishimura, K. Sasaki, and T. Hashimoto are employees of Mitsubishi Tanabe Pharma Corporation.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number H-22-014) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.